Title : c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy.

Pub. Date : 1999 Apr-Jun

PMID : 10399623






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 In a therapy optimizing study with weekly dose-intensified paclitaxel monotherapy (schedule: 90 mg/m2 weekly x 6, q9w), we correlated the clinical course of stage IV breast cancer in UICC criteria with the course of the shed c-erbB-2 protein fragment and the CA 27.29 serum level. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 While the overall response rate in the study is 36%, the response rate among c-erbB-2-positive patients is 62%, indicating a high sensitivity of c-erbB-2 positive patients to dose-intense paclitaxel treatment. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens
4 While the overall response rate in the study is 36%, the response rate among c-erbB-2-positive patients is 62%, indicating a high sensitivity of c-erbB-2 positive patients to dose-intense paclitaxel treatment. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens